A Brief Report on Proposed Areas of International Harmonization of Real‐World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators
Pharmacoepidemiology and Drug Safety · 2025
DOI: 10.1002/pds.70127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2025. Verfasst von Maryam Nafie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Duke-Robert J. Margolis, MD, Institute for Health Policy, Duke University, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Pharmacoepidemiology. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
International harmonization of real‐world data and evidence (RWD/E) standards is a goal among real‐world data/real‐world evidence (RWD/E) policy stakeholders. The Duke‐Robert J. Margolis Institute for Health Policy developed an online ‘International Harmonization of RWE Standards Dashboard’ to provide timely updates around these goals.
Methods
Guidance for industry (draft and final) and related literature available online by medical product regulators globally was sought and, where needed, translated into English language using a certified translator. Consultations were then held with practicing experts to identify, collate, and interpret documents. An online Tableau tool was assembled to collate guidance documents and regulatory definitions of the following key terms used among the community to describe fit‐for‐use RWE in regulatory submissions: relevance, reliability, and quality.
Results
As of February 2025, the United States Food and Drug Administration (FDA) has released the most RWE guidance documents to date ( n = 13; 4 draft, 9 final). Four (4) regulators globally (US FDA, EMA, Taiwan FDA, Brazil ANVISA) have directly defined at least two (2) out of the three key terms (reliability, relevance, quality), indicating alignment around the importance of these terms used in the context of RWD/E. Across these terms, we propose areas of definitional alignment: data representativeness and research and regulatory concern (relevance), accuracy in data interpretation and quality and integrity during data accrual (reliability), and data quality assurance across sites and time (quality). We propose areas of definitional misalignment regarding clinical context, data availability and representativeness, and ensuring study sample sizes and/or datasets are adequate to address a given study question.
Conclusions
Our assessment of definitions provided among these four regulators lends us to propose distinct areas for harmonization based on our assessment of where regulators appear to align and highlight opportunities to address misalignment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Duke-Robert J. Margolis, MD, Institute for Health Policy, Duke University, Washington, District of Columbia, USA.
Zitieren
APA
Nafie, M., Parker, V. J., McClellan, M., & Hendricks-Sturrup, R. M. (2025). A Brief Report on Proposed Areas of International Harmonization of Real‐World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70127
Vancouver
Nafie M, Parker VJ, McClellan M, Hendricks-Sturrup RM. A Brief Report on Proposed Areas of International Harmonization of Real‐World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators. Pharmacoepidemiology and Drug Safety. 2025. doi:10.1002/pds.70127
BibTeX
@article{Nafie2025,
author = {Nafie, Maryam and Parker, Valerie J and McClellan, Mark and Hendricks-Sturrup, Rachele M},
title = {A Brief Report on Proposed Areas of International Harmonization of Real‐World Evidence Relevance, Reliability and Quality Standards Among Medical Product Regulators},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
doi = {10.1002/pds.70127}
}
EUVIMED